Aryx Therapeutics (ARYX) 0.0027 $ARYX
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 269.16 (-10.72), ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AVEO: 1.27 (+0.05), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
Global Pharma and Biotech M&A Trends 2010-2015: Access to Agreements Entered into by the World's Leading Biopharma Companies
M2 - Tue Sep 22, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hw5rqj/global_pharma_and) has announced the addition of the "Global Pharma and Biotech M&A Trends 2010-2015 (8th Edition)" mergers & acquisitions to their offering. The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners. Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits: - In-depth understanding of M&A deal trends since 2010. - Analysis of the structure of M&A agreements with numerous real life case studies. - Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available. - Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies. - Insight into the terms included in a M&A agreement, together with real world clause examples. - Full listing of M&A deals by company A-Z and industry sector. - Understand the key deal terms companies have agreed in previous deals. - Undertake due diligence to assess suitability of your proposed deal terms for partner companies. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Trends in M&A dealmaking Chapter 3 - Overview of M&A deal structure Chapter 4 - Leading M&A deals Chapter 5 - Big pharma M&A deals Chapter 6 - Big biotech M&A deals Chapter 7 - M&A contracts directory Companies Mentioned - 30 of the 100 Companies - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys - Atley Pharmaceuticals - Auriga Laboratories - Aventis - AVEO Pharmaceuticals - Barrier Therapeutics - Bayer - Biogen Idec - BioMarin Pharmaceuticals - BioMerieux For more information visit http://www.researchandmarkets.com/research/hw...pharma_and
BIIB: 269.16 (-10.72), ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AVEO: 1.27 (+0.05), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 41.89 (+0.73), AMGN: 149.59 (-0.31), AGN: 274.84 (-1.32), ACAD: 32.43 (+0.35), ACHN: 7.57 (-0.10), AEZS: 0.09 (unch), ANAC: 115.06 (+2.13), XLRN: 24.08 (-0.18)
